Boston-based health tech startup Biofourmis enters the Unicorn Club ($1 billion in valuation). The startup raised $300 million in its Series D funding round led by General Atlantic. Their current value has reached $1.3 billion. Other participants in the round were CVS Health and existing investors. 

Founded by Kuldeep Singh Rajput and co-founded by Mark Niu and Maulik Majumdar, the startup provides personalised and predictive care for patients. The startup has FDA approved hardware and software solutions to detect and predict diseases in patients. The startup believes that personalised patient care makes a great impact on the health and wellbeing of the patient.  

This round brings the startup’s total fund raised to around $445 million. They had raised $35 million in their Series B round and $100 million in their Series C round. Its investors include MassMutual Ventures, Sequoia Capital, SoftBank Vision Fund, Aviva Ventures, Openspace, Eden Strategy Insititute, SpesNet Pte. Ltd., EDBI and many more. 

CDC estimates that 6 in 10 American adults have 1 chronic disease whereas 4 in 10 suffer from 2 or more chronic diseases. The venture has 2 subsets - Biofourmis Therapeutics and Biofourmis Health. The startup's two acquisitions include a wearable biosensor named Biovotion and Takeda Pharmaceutical’s oncology-focused digital therapeutics company Gaido Health.